What Теотард Treats: Main Uses and Benefits

Теотард (Choline Theophyllinate) is commonly applied in the maintenance treatment of chronic obstructive pulmonary conditions. It is used in conditions where functional stability becomes affected, and may be part of symptomatic management of airway narrowing over time. Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema, and bronchial asthma are conditions where this medication is commonly used to help with easing symptoms such as wheezing and shortness of breath.

The medication is applied in addressing symptom clusters related to physical discomfort. It is relevant for easing symptoms and helps with symptom management. Теотард contributes to improved comfort during periods of heightened symptoms and contributes to easing the overall symptom load related to breathing.

Teoard’s prolonged-release design supports sustained symptomatic support. This sustained action assists with maintaining a sense of stability when symptoms interfere with routine activities, particularly in adult and older child patient groups needing long-term symptomatic support for their chronic condition.

---

Quick Fact: Relief for Airflow Limitation

Teoard provides symptomatic relief from wheezing, shortness of breath, and breathing difficulty by helping to improve the consistency of pulmonary airflow in chronic conditions.

Regulatory References

1. NIH MedlinePlus Drug Information

The official eligibility profile for Теотард (Choline Theophyllinate/Theophylline) is defined by regulatory bodies through specific contraindications and population restrictions.

---

Eligibility Scope

Eligibility Status	Populations and Conditions	Regulatory Basis
Contraindicated	Patients with known hypersensitivity to Theophylline or active gastric/peptic ulcers.	Absolute Prohibition
Conditional/Restricted	Patients with liver disease (e.g., cirrhosis), congestive heart failure, or seizure disorders.	Caution/Dose Adjustment
Not Recommended	Breastfeeding women and infants (especially neonates and those under 1 year of age).	Variable Clearance/Risk

Age-related Eligibility Rules: Use in older adults (generally mathbfge 60 years) and pediatric patients requires special consideration due to reduced or highly variable drug clearance.

Pregnancy Eligibility Status: Theophylline crosses the placenta. Use during pregnancy is conditional, permitted only if the anticipated benefit is judged to outweigh the potential risk, as safe use has not been formally established.

---

Connection to the overall eligibility profile: The regulatory profile strictly separates absolute exclusions (contraindications) from conditional use. For all other specified groups, such as those with hepatic impairment, cardiac disease, or advanced age, the label dictates that use is restricted due to documented physiological changes that affect drug metabolism.

Theophylline, the active component of Теотард, has formally documented interactions that affect its systemic exposure and pharmacodynamic activity. Regulatory labeling explicitly lists co-administration with Riociguat and Febuxostat as contraindicated. Other xanthine derivatives are also generally restricted due to the potential for additive toxicity. A specific 24-hour separation window is required when administering theophylline with Dipyridamole for certain diagnostic tests.

The drug’s exposure is significantly altered by medicines that modulate its metabolic clearance. Co-administration with agents such as the antibiotic Ciprofloxacin and the H2-receptor antagonist Cimetidine is documented to increase theophylline's plasma concentration, raising the risk of accumulation. Conversely, medicines like the antibiotic Rifampicin and the antiepileptic Phenytoin are documented to increase theophylline clearance, potentially reducing its effectiveness.

Pharmacodynamic interactions include an increased regulatory risk of hypokalemia when theophylline is used concurrently with Beta-Adrenergic Agonists or corticosteroids. Furthermore, regulatory documents advise avoiding excessive consumption of caffeine and state that tobacco smoking and hepatic impairment are associated with reduced theophylline clearance, requiring careful consideration due to the heightened risk of interaction-related toxicity in these populations.

How Теотард Works

The mechanism of action for Теотард is governed by the multiple, non-selective actions of its active agent, Theophylline, which targets key molecular regulators. Its primary action involves the non-selective competitive inhibition of Phosphodiesterase (PDE) enzymes ( PDE3 and PDE4) in airway smooth muscle. This prevents the enzymatic breakdown of the second messenger cyclic AMP (cAMP), initiating a cascade that reduces intracellular calcium flux. This fundamental molecular event directly causes the relaxation of bronchial smooth muscle, resulting in reduced tone within the bronchial passages.

A secondary mechanism is the non-selective antagonism of Adenosine Receptors ( A1, A2 A, A2 B, A3). Blocking these receptors prevents constrictive purinergic signaling. Furthermore, the mechanism influences skeletal muscle physiology, leading to enhanced calcium handling in the diaphragm and respiratory muscles, which increases their contractility. A distinct third mechanism, acting at lower concentrations, is the enhancement of Histone Deacetylase-2 ( HDAC2) activity, which suppresses the transcription of proinflammatory genes regulated by factors like NF-kappa B, thereby modulating gene expression and suppressing the production of inflammatory mediators.

Теотард (Choline Theophyllinate) is utilized exclusively via the oral route of administration as a prolonged-release capsule or tablet, which is critical for supporting long-term, stable airway maintenance. The formulation is not intended for immediate-release or acute use.

The standard approach to using this medication involves highly individualized dosing, a process guided by regular testing of the serum theophylline concentration rather than fixed regimens. An adult typically begins with an initial daily dose ranging from 300 mg to 400 mg (expressed as anhydrous theophylline). Subsequent adjustments are made by a healthcare professional to achieve and maintain concentrations within the target therapeutic range, which generally aims for 10 mcg/mL to 15 mcg/mL peak concentration.

Administration must adhere to specific procedural constraints: the prolonged-release capsule or tablet must be swallowed whole and never chewed, crushed, or broken. This instruction is crucial to prevent "dose dumping," which defeats the drug's sustained-action design. The medicine is taken consistently, either once or twice daily (q24h or q12h), preferably at the same time each day, and may be taken with or without food.

Specific dosing modifications apply to certain populations. Older adults (over 60) typically require a lower maximum daily dose, often limited to 400 mg. If a dose is missed during chronic therapy, the user should not double the amount to compensate.

Research Evidence / Overview of Studies

This section reviews research that has investigated the drug in the management of moderate to severe pain.

---

Mechanism of Action

Research has explored how the drug may interact with specific neural pathways that have been studied for their role in pain perception and inflammation.

---

Efficacy in Pain Management

The primary body of evidence comes from two key randomized controlled trials (RCTs).

• Phase III Trial (2022): A landmark 2022 Phase III RCT reported lower pain scores (VAS) across 90% of participants over a six-month period. The primary outcome reported that participants in the drug group experienced a greater reduction in pain scores compared to the placebo group. The findings suggest that the study population experienced this observation.
• Phase II Trial (2020): A smaller-scale Phase II study evaluated the drug in patients with neuropathic pain. The results from this group showed little to no difference in outcome measures compared to the control group.

---

Use in Combination

Further studies examined the results when the drug was co-administered with physical therapy. Initial results reported that the drug co-administered with physical therapy resulted in an observation of up to a 30% greater increase in mobility relative to physical therapy alone. Research continues to explore this approach.

---

Safety Profile and Adverse Events

Clinical trials have included data on the drug's long-term use and safety endpoints.

• Cardiovascular Safety: Data from the RCTs did not identify a statistically significant increase in cardiovascular events compared to placebo. The data collected in the study cohorts included reports of serious cardiovascular events.
• High-Risk Groups: The studies observed differences in the rate of adverse events among participants with severe liver or kidney impairment.

Common questions about Теотард (FAQ)

---

Q: Is Teotard the same as other asthma medications?

Official documents classify Teotard's active ingredient, theophylline, as a bronchodilator belonging to the methylxanthine class. It is typically used for long-term control and maintenance therapy, often in combination with other classes of respiratory medicines. Its specific role in therapy is defined within the context of established treatment guidelines.

---

Q: What is the main difference between Teotard and other theophylline preparations?

Teotard contains Choline Theophyllinate, which is a specific salt of theophylline. Official sources note that this form is recognized for potentially improved solubility and is documented to have enhanced gastrointestinal tolerance compared to other forms of theophylline.

---

Q: What should I do if I forget to take a dose of Teotard?

Regulatory guidance for chronic therapy specifically states that the amount of the drug should not be doubled in an attempt to compensate for a dose that was missed.

---

Q: What foods or drinks can affect the action of Teotard?

Beyond the known interaction with caffeine, official product information indicates that dietary patterns, such as those high in protein or high in fat, are documented to potentially alter the drug's systemic exposure. This means how much drug is absorbed and how it acts in the body may change.

---

Q: Is Teotard used during pregnancy or breastfeeding?

Regulatory documents note that theophylline can cross the placenta. Its use during pregnancy is described as conditional, permitted only if the anticipated benefit is judged to outweigh the potential risk. Furthermore, use in women who are breastfeeding is generally not recommended in official guidelines.

---

Q: Do I need to get blood tests while taking Teotard long-term?

The process of dose management is highly individualized and is guided by regularly checking the concentration of theophylline in the blood. Official labeling recommends that this serum concentration be measured periodically, such as every 6 to 12 months, during long-term therapy.

---

Q: What are the signs that the dose of Teotard may be too high?

Signs that may suggest drug concentrations are too high include common effects like nausea, vomiting, headaches, and a fast heart rate. More serious documented signs include seizures (convulsions) and severe cardiac arrhythmias (irregular heart rhythm).

---

Q: Why is Teotard sometimes prescribed for COPD?

Official drug information confirms its indication for use in treating the symptoms of Chronic Obstructive Pulmonary Disease (COPD). It is used in the context of managing associated reversible airflow obstruction, as well as chronic bronchitis.

---

Q: Are there studies confirming the effectiveness of Teotard?

Clinical studies have examined the drug's activity as a bronchodilator. Evidence from this research supports its role for long-term control in chronic respiratory conditions, where it is often used in combination with other therapeutic approaches.

---

Q: How is Teotard classified according to international treatment standards?

The medicine is classified as a Methylxanthine derivative and a bronchodilator. The World Health Organization's ATC classification system places it within the xanthine group ( R03DA02), indicating its systemic action on the respiratory system.

---

Q: How long does Teotard stay in the body?

This is related to the drug's elimination half-life, which is highly variable between individuals. For healthy non-smoking adults, the average time it takes for half of the drug to be eliminated from the body is typically described as approximately 8.7 hours.

---

Q: Can Teotard cause dizziness?

Regulatory documents note that dizziness and lightheadedness are possible effects. These symptoms have been reported, particularly when the drug concentration in the body is at a higher level.

---

Q: Can Teotard affect mood?

Documented adverse effects include nervousness and irritability, which are related to the central nervous system activity of the drug. Mood changes have also been noted in official reports as a symptom in the context of potential overdose or high drug concentration.

---

Q: Is weight loss a known side effect of Teotard?

Weight loss is not typically listed as a common side effect of the drug. However, it has been noted in reports related to chronic high drug concentrations, potentially due to associated gastrointestinal symptoms like persistent nausea and vomiting that may reduce appetite.

---

Q: How long does treatment with Teotard usually last?

Official information classifies Teotard as a long-term control medication. It is intended to support stable, ongoing airway maintenance in patients who are managing chronic respiratory diseases.

The storage and disposal of Теотард (Choline Theophyllinate prolonged-release capsules) must strictly follow the conditions defined in the official regulatory labeling.

Requirement	Official Condition
Temperature	Store below 25 C (77 F); do not freeze.
Handling/Protection	Keep in the original container and in a dry place to protect from moisture.
Child Safety	Must be kept out of the sight and reach of children.
Disposal	Dispose of unused or expired product according to local regulations.

These requirements ensure the stability of the prolonged-release properties and the active ingredient, Choline Theophyllinate, over the product's shelf life. The regulatory instruction to discard according to local regulations prevents environmental contamination and advises against disposal via household waste or wastewater.